内静止素和细胞静止素C作为预测1个月的功能变化在患者的左心室辅助设备支持的左心室辅助设备
Shiyi Li1, Katherine V Nordick1, Iván Murrieta-Álvarez1
1From the Division of Cardiothoracic Transplantation and Circulatory Support, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
ASAIO journal (American Society for Artificial Internal Organs : 1992)
|March 10, 2025
概括
在左心室辅助装置 (LVAD) 植入后预测功能改善至关重要. 基线内静止素和早期手术后的cystatin C水平可以识别患有急性损伤 (AKI) 和功能改善 (RFI) 风险的患者.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 生物标志物发现发现
背景情况:
- 在LVAD植入后的功能轨迹非常可变.
- 在LVAD后,功能改善不良 (RFI) 和急性损伤 (AKI) 与死亡率增加有关.
- 确定RFI和AKI的预测生物标志物对于患者管理至关重要.
研究的目的:
- 在LVAD植入后一个月内评估血内静止素和细胞静止素C作为RFI和AKI的预测因子.
- 为了确定患有LVAD后脏不良结果高风险的患者.
主要方法:
- 预期招募52名接受LVAD植入的晚期心力衰竭患者.
- 在植入前和植入后四周内每周进行连续取血样.
- 测量血内静止素和细胞静止素C水平.
主要成果:
- 46.2%的患者实现了RFI; 53.8%没有.
- 在没有RFI的人中,53.6%的人发展了AKI.
- 基线内静止素 (p=0.012) 和细胞质素C (p=0.045) 预测了RFI.
- 在高风险患者中,术后第1周的囊素C水平区分了AKI与非AKI.
- 基线高的内静止素确定了患有适应能力降低的患者.
结论:
- 基线内静止素可以在LVAD前识别患有适应能力下降的患者.
- 术后第1周,氨酸C是预测高风险患者 (没有RFI的患者) 的AKI的一个有价值的生物标志物.
- 结合对基线内静止素和早期术后囊素C的监测,可以早期检测和管理LVAD后的功能障碍.
相关概念视频
01:22Heart Failure Drugs: Diuretics
318
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
318
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
360
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
360
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
76
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
76
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
40
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
40